Bio-Techne Holders Approve Merck KGaA's $11.3 Billion Buyout — and Reject the Executive Pay Package Nearly 4 to 1

The merger passed with 121.9 million shares in favor against 1.2 million opposed, while the advisory golden-parachute proposal failed with 96.4 million against.

By Anna Ferreira

Sep 25, 2026 · 3 min read

Bio-Techne shareholders approved Merck KGaA's $73.00-a-share cash acquisition of the life-sciences group at a special meeting on Sept. 23, while decisively rejecting the advisory proposal on compensation payable to executives in connection with the deal.

Discussion (0)

Loading comments…

Anna Ferreira

Senior Correspondent, Corporate Strategy

Anna Ferreira writes for Corporate Insider Inc.

CII Briefing

The 7am memo for people who run things

One email. The deals, the numbers and the decisions that will be discussed in your Monday meeting.